Loading…
← CockpitCompetitor Analysis › GUJTHEM.NS Gujarat Themis Biosyn LtdOpen in the cockpit ↗

Gujarat Themis Biosyn LtdGUJTHEM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum neutral 54
Mkt cap
$505M
US dollars, full cap
Free float
39%
of shares outstanding
$/day
$837,096
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.4 pp
WACC 20.0%
Hurdle
n/a
no reverse DCF
Close · INR₹362.80
1D+4.0%
1W-7.3%
1M+1.2%
3M-2.3%
6M+1.8%
YTD-17.9%
1Y-19.4%
ATR %5.2%
Beta1.38
52w lowhigh22.8% off high

What Gujarat Themis Biosyn does

Employees: 379

Gujarat Themis Biosyn at a glance

Size Gujarat Themis Biosyn (GUJTHEM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $505M, the 842nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹362.80 on 18 Nov 2026.

Performance Over six months the shares gained 1.8%, against -19.6% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 17.5% over the last twelve months (peer median +9.4%); the operating margin is 38.9% (peer median 10.9%).

Valuation It trades at 27.2× enterprise value to sales against a peer median of 3.7× (2nd most expensive of 20).

Capital Return on invested capital runs 2.4 points below its cost of capital (20.0% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026GUJTHEM.NS 102Peer median 81
Six months, rebased to 100: Gujarat Themis Biosyn against the median of its 20 peers (local-currency closes).

Gujarat Themis Biosyn financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹1.74B₹1.66B₹1.51B₹1.70B₹1.48B
Revenue growth—+10%-11%+14%—
Gross profit₹822M₹769M₹737M₹863M₹797M
EBITDA₹824M₹772M₹709M₹788M₹748M
Net income₹487M₹467M₹488M₹592M₹580M
Free cash flown/a-₹1.28B-₹220M-₹94.3M₹99.2M
Capital expendituren/a₹1.73B₹1.16B₹746M₹237M
Total debtn/a₹1.62B₹305M₹27.7M₹4.19M

Quarterly statements and history in the cockpit →

Gujarat Themis Biosyn competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%INDP603207EGTXGYRE603676600222TKNO600513003090AARTIDRUGS1666301277003020SUPRIYAGUJTHEM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Gujarat Themis Biosyn is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×25×50×75×603207EGTXGYRE603676600222TKNO6005130030903004851666300584003020EVONILESUPRIYA688373GUJTHEM.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Gujarat Themis Biosyn is the large dot.

Gujarat Themis Biosyn competitors and peer comparison

How Gujarat Themis Biosyn compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Gujarat Themis Biosyn against its 20 peers (data as of 18 Nov 2026)
MeasureGUJTHEM.NSPeer medianRank in peer set
1-month return+1.2%-7.0%5th highest of 20
6-month return+1.8%-19.6%5th highest of 20
Distance from 52-week high-22.8%-39.7%4th highest of 20
Revenue growth (TTM)+17.5%+9.4%5th highest of 20
Operating margin38.9%10.9%2nd highest of 20
EV / Sales27.2×3.7×2nd most expensive of 20
ROIC minus cost of capital-2.4 pp-2.2 pp10th highest of 19
EV / EBITDA57.3×9.7×most expensive of 5
Net debt / EBITDA1.9×1.6×3rd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a

Questions

Which companies are Gujarat Themis Biosyn's closest peers?
The cockpit's peer set: Indaptus Therapeutics (INDP), Shanghai Xiao Fang Pharmaceutical (603207.SS), Egetis Therapeutics (EGTX.ST), Gyre Therapeutics (GYRE), Xizang Weixinkang Pharmaceutical (603676.SS), Henan Taloph Pharmaceutical Stock (600222.SS), Alpha Teknova (TKNO), Jiangsu Lianhuan Pharmaceutical (600513.SS).
Is Gujarat Themis Biosyn expensive compared with its peers?
On ev / sales it trades at 27.2× against a peer median of 3.7×, 2nd most expensive of 20 in its peer set.
How has Gujarat Themis Biosyn stock performed?
Over six months to 18 Nov 2026 the shares returned +1.8% against -19.6% for the median peer; over one year -19.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.